GHRP-6
Hormonal and Signaling
ABOUT
GHRP-6 is a synthetic growth-hormone-releasing peptide. A small pharmacokinetic study in healthy male volunteers measured its disposition after a single intravenous administration.
EVIDENCE OVERVIEW
Early human findings, not yet confirmed
WHAT THIS MEANS
Potential. Review the research and limitations before relying on this record.
IDENTITY
HALF-LIFE
HOW IT IS THOUGHT TO WORK
GHRP-6 is a synthetic hexapeptide agonist at the growth-hormone-secretagogue receptor. It stimulates GH release and, through the same ghrelin-receptor pathway, markedly stimulates appetite - the appetite effect is a direct consequence of the mechanism, not a side effect of it. Like GHRP-2 it also raises prolactin and ACTH/cortisol.
PHARMACOKINETICS
A dedicated pharmacokinetic study in nine healthy male volunteers characterised its disposition after single intravenous administration - GHRP-6 is the best-characterised of this family in that respect. The class is described as active by intravenous, subcutaneous, intranasal and oral routes, but subcutaneous parameters are not curated here, and urinary metabolites have been characterised for doping control after nasal administration.
REVIEW
PUBLISHED PAIR RECORDS
with CJC-1295 (without DAC)
Growth-hormone axis: documented synergistic releaseCJC-1295 (without DAC) acts at the GHRH receptor while GHRP-6 acts at the ghrelin/GH-secretagogue receptor. In healthy men, submaximal doses of a GH-releasing peptide combined with GHRH stimulated GH release synergistically rather than additively, and the combined area-under-curve response exceeded the arithmetic sum of each given alone. Combining these two classes therefore produces a larger GH and downstream IGF-1 response than either alone. GHRP-6 also raises prolactin, ACTH and cortisol; in a head-to-head human comparison the ACTH/cortisol-releasing activity of GHRP-2 and hexarelin was similar to that of CRH, while prolactin release was lower than that of TRH. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with CJC-1295 with DAC
Growth-hormone axis: documented synergistic releaseCJC-1295 with DAC acts at the GHRH receptor while GHRP-6 acts at the ghrelin/GH-secretagogue receptor. In healthy men, submaximal doses of a GH-releasing peptide combined with GHRH stimulated GH release synergistically rather than additively, and the combined area-under-curve response exceeded the arithmetic sum of each given alone. Combining these two classes therefore produces a larger GH and downstream IGF-1 response than either alone. GHRP-6 also raises prolactin, ACTH and cortisol; in a head-to-head human comparison the ACTH/cortisol-releasing activity of GHRP-2 and hexarelin was similar to that of CRH, while prolactin release was lower than that of TRH. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with Sermorelin
Growth-hormone axis: documented synergistic releaseSermorelin acts at the GHRH receptor while GHRP-6 acts at the ghrelin/GH-secretagogue receptor. In healthy men, submaximal doses of a GH-releasing peptide combined with GHRH stimulated GH release synergistically rather than additively, and the combined area-under-curve response exceeded the arithmetic sum of each given alone. Combining these two classes therefore produces a larger GH and downstream IGF-1 response than either alone. GHRP-6 also raises prolactin, ACTH and cortisol; in a head-to-head human comparison the ACTH/cortisol-releasing activity of GHRP-2 and hexarelin was similar to that of CRH, while prolactin release was lower than that of TRH. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with Tesamorelin
Growth-hormone axis: documented synergistic releaseTesamorelin acts at the GHRH receptor while GHRP-6 acts at the ghrelin/GH-secretagogue receptor. In healthy men, submaximal doses of a GH-releasing peptide combined with GHRH stimulated GH release synergistically rather than additively, and the combined area-under-curve response exceeded the arithmetic sum of each given alone. Combining these two classes therefore produces a larger GH and downstream IGF-1 response than either alone. GHRP-6 also raises prolactin, ACTH and cortisol; in a head-to-head human comparison the ACTH/cortisol-releasing activity of GHRP-2 and hexarelin was similar to that of CRH, while prolactin release was lower than that of TRH. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with Ipamorelin
Same receptor class: overlapping ghrelin-receptor activityIpamorelin and GHRP-6 both act as agonists at the ghrelin/GH-secretagogue receptor, so they compete for the same receptor population instead of adding a second mechanism. One of the pair is non-selective and raises prolactin, ACTH and cortisol alongside GH in human dose-response studies. Human data also indicate the GH response to sustained secretagogue exposure attenuates partially and reversibly over weeks. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with GHRP-2
Same receptor class: overlapping ghrelin-receptor activityGHRP-2 and GHRP-6 both act as agonists at the ghrelin/GH-secretagogue receptor, so they compete for the same receptor population instead of adding a second mechanism. Both are non-selective: human dose-response data show each raises prolactin, ACTH and cortisol alongside GH, so those off-target endocrine effects overlap. Human data also indicate the GH response to sustained secretagogue exposure attenuates partially and reversibly over weeks. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with Hexarelin
Same receptor class: overlapping ghrelin-receptor activityGHRP-6 and Hexarelin both act as agonists at the ghrelin/GH-secretagogue receptor, so they compete for the same receptor population instead of adding a second mechanism. Both are non-selective: human dose-response data show each raises prolactin, ACTH and cortisol alongside GH, so those off-target endocrine effects overlap. Human data also indicate the GH response to sustained secretagogue exposure attenuates partially and reversibly over weeks. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with MK-677
Same receptor class: overlapping ghrelin-receptor activityGHRP-6 and MK-677 both act as agonists at the ghrelin/GH-secretagogue receptor, so they compete for the same receptor population instead of adding a second mechanism. One of the pair is non-selective and raises prolactin, ACTH and cortisol alongside GH in human dose-response studies. Human data also indicate the GH response to sustained secretagogue exposure attenuates partially and reversibly over weeks. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with IGF-1 LR3
Additive IGF-1 receptor signallingGHRP-6 raises IGF-1 indirectly by stimulating growth-hormone release, while IGF-1 LR3 is an IGF-1 analogue that acts directly at the IGF-1 receptor. The two therefore converge on the same downstream signalling. Regulatory labelling for recombinant IGF-1 records that the IGF-1 receptor is homologous to the insulin receptor, that IGF-1 has insulin-like hypoglycaemic effects, and that hypoglycaemia is among its most common adverse effects; doses of insulin or other hypoglycaemic products may need reducing. Growth hormone itself moves blood glucose in the opposite direction, so the net glycaemic effect of the pair is not predictable from either agent alone. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with IGF-1 DES
Additive IGF-1 receptor signallingGHRP-6 raises IGF-1 indirectly by stimulating growth-hormone release, while IGF-1 DES is an IGF-1 analogue that acts directly at the IGF-1 receptor. The two therefore converge on the same downstream signalling. Regulatory labelling for recombinant IGF-1 records that the IGF-1 receptor is homologous to the insulin receptor, that IGF-1 has insulin-like hypoglycaemic effects, and that hypoglycaemia is among its most common adverse effects; doses of insulin or other hypoglycaemic products may need reducing. Growth hormone itself moves blood glucose in the opposite direction, so the net glycaemic effect of the pair is not predictable from either agent alone. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with follistatin-344
Converging on muscle growth from two different directionsFollistatin-344 antagonises myostatin and activin A, removing a brake on skeletal-muscle growth through the SMAD2/3 pathway. GHRP-6 pushes the accelerator instead, raising growth-hormone exposure and downstream IGF-1. These are genuinely distinct pathways converging on the same tissue outcome, which is why the combination is attractive in principle and why its size cannot be predicted from either alone. The evidence does not support treating it as characterised: human follistatin data comes from AAV-delivered gene therapy in open-label muscular-dystrophy trials of a handful of patients, not from injected follistatin protein, and a case series reported central serous chorioretinopathy in bodybuilders using subcutaneous FS-344. Growth factors affecting muscle regeneration are prohibited at all times in sport. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 21 Aug 2026with AOD-9604
Growth-hormone fragment that does not act through the growth-hormone receptorAOD-9604 is the C-terminal fragment of human growth hormone (residues 177-191), and it is commonly scheduled alongside growth-hormone secretagogues on the assumption that it adds to the same axis. It does not: the fragment was designed to reproduce the lipolytic action of growth hormone without its diabetogenic effects, and published work shows its lipolytic action is not mediated directly through the growth hormone receptor. GHRP-6 raises endogenous growth hormone and downstream IGF-1; AOD-9604 does not add to that signal. The more relevant fact is efficacy: FDA's review describes a 502-person obesity trial in which AOD-9604 showed no significant difference from placebo on its primary endpoint, and development did not proceed to approval. AOD-9604 is prohibited by the World Anti-Doping Agency. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 21 Aug 2026with CJC-1295 / GHRP-6 blend
Same substance taken twice: blend already contains this compoundCJC-1295 / GHRP-6 blend already contains GHRP-6. Scheduling the standalone compound alongside the blend means taking it twice from two sources, and the blend's other components come with it whether or not they are wanted at that moment. This is the one exposure risk a blend creates that its individual parts do not, and it is arithmetic rather than pharmacology - the combined amount is whatever the two products add up to. Where a blend's ratio is fixed by the manufacturer, the only way to change one component's dose is to add or remove the whole vial. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with CJC-1295 / Ipamorelin blend
Inherited from a component of this blendCJC-1295 / Ipamorelin blend contains CJC-1295 (without DAC) and Ipamorelin, and the catalogue holds a curated pair record between those components and GHRP-6: CJC-1295 (without DAC) (growth-hormone axis: documented synergistic release); Ipamorelin (same receptor class: overlapping ghrelin-receptor activity). Taking the blend therefore carries the same consideration as taking that component on its own, with the difference that a fixed-ratio vial cannot be adjusted independently of the rest of its contents. The evidence and citations here are the component record's; nothing has been studied about the blend itself. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with CJC-1295 with DAC / Ipamorelin blend
Inherited from a component of this blendCJC-1295 with DAC / Ipamorelin blend contains CJC-1295 with DAC and Ipamorelin, and the catalogue holds a curated pair record between those components and GHRP-6: CJC-1295 with DAC (growth-hormone axis: documented synergistic release); Ipamorelin (same receptor class: overlapping ghrelin-receptor activity). Taking the blend therefore carries the same consideration as taking that component on its own, with the difference that a fixed-ratio vial cannot be adjusted independently of the rest of its contents. The evidence and citations here are the component record's; nothing has been studied about the blend itself. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with Sermorelin / Ipamorelin blend
Inherited from a component of this blendSermorelin / Ipamorelin blend contains Sermorelin and Ipamorelin, and the catalogue holds a curated pair record between those components and GHRP-6: Sermorelin (growth-hormone axis: documented synergistic release); Ipamorelin (same receptor class: overlapping ghrelin-receptor activity). Taking the blend therefore carries the same consideration as taking that component on its own, with the difference that a fixed-ratio vial cannot be adjusted independently of the rest of its contents. The evidence and citations here are the component record's; nothing has been studied about the blend itself. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with CJC-1295 / GHRP-2 blend
Inherited from a component of this blendCJC-1295 / GHRP-2 blend contains CJC-1295 (without DAC) and GHRP-2, and the catalogue holds a curated pair record between those components and GHRP-6: CJC-1295 (without DAC) (growth-hormone axis: documented synergistic release); GHRP-2 (same receptor class: overlapping ghrelin-receptor activity). Taking the blend therefore carries the same consideration as taking that component on its own, with the difference that a fixed-ratio vial cannot be adjusted independently of the rest of its contents. The evidence and citations here are the component record's; nothing has been studied about the blend itself. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with CJC-1295 / Hexarelin blend
Inherited from a component of this blendCJC-1295 / Hexarelin blend contains CJC-1295 (without DAC) and Hexarelin, and the catalogue holds a curated pair record between those components and GHRP-6: CJC-1295 (without DAC) (growth-hormone axis: documented synergistic release); Hexarelin (same receptor class: overlapping ghrelin-receptor activity). Taking the blend therefore carries the same consideration as taking that component on its own, with the difference that a fixed-ratio vial cannot be adjusted independently of the rest of its contents. The evidence and citations here are the component record's; nothing has been studied about the blend itself. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026HUMAN EVIDENCE
GHRP-6 demonstrated marked, dose-related GH release in humans, and an increase in height velocity was reported during chronic treatment in short children. That is the extent of the controlled human record; it was not developed to approval for any indication, and no trial supports the body-composition uses it is marketed for.
REPORTED EFFECTS
Pronounced appetite stimulation is expected from the mechanism. The class also produces prolactin and ACTH/cortisol release. Controlled adverse-effect rates are not reported in the indexed reviews. No regulator has approved this substance for the use described here, so there is no label-verified dose, purity standard, or safety monitoring requirement behind it.
RESEARCH LIMITATIONS
This is a small pharmacokinetic study and not evidence of benefit or long-term safety. It does not support a schedule or dose recommendation.
CURATED SOURCES · 3